Immunotech Biopharm Ltd (HKG:6978)

Immunotech Biopharm Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	44.54	53.22	97.71	104.25	68.63
Research & Development	154.24	177.33	176.22	240.61	278.63
Other Operating Expenses	2.12	0.5	0.29	0.29	0.47
Operating Expenses	200.9	231.05	274.22	345.15	347.72
Operating Income	-200.9	-231.05	-274.22	-345.15	-347.72
Interest Expense	-7.49	-8.52	-6.14	-3.68	-2.39
Interest & Investment Income	1.07	3.01	3.2	7.56	3.65
Currency Exchange Gain (Loss)	0.22	-0.07	0.09	-6.27	-40.53
Other Non Operating Income (Expenses)	60.39	-9.23	-5.62	10.51	-35.23
EBT Excluding Unusual Items	-146.71	-245.85	-282.69	-337.03	-422.22
Gain (Loss) on Sale of Investments	-19.81	-90.01	-24.02	-18.79	-
Gain (Loss) on Sale of Assets	-0.04	0.2	-0.64	-0.09	0.08
Asset Writedown	-19.88	-	-	1.3	-
Other Unusual Items	0.02	0.19	-13.75	-	-16.98
Pretax Income	-186.42	-335.48	-321.1	-354.62	-439.13
Income Tax Expense	0.93	-	-	-	-
Earnings From Continuing Operations	-187.34	-335.48	-321.1	-354.62	-439.13
Minority Interest in Earnings	0.43	0.66	2.99	0.39	0.08
Net Income	-186.91	-334.82	-318.11	-354.22	-439.05
Net Income to Common	-186.91	-334.82	-318.11	-354.22	-439.05
Shares Outstanding (Basic)	515	515	515	515	444
Shares Outstanding (Diluted)	515	515	515	515	444
Shares Change (YoY)	-	-	-	15.95%	16.82%
EPS (Basic)	-0.36	-0.65	-0.62	-0.69	-0.99
EPS (Diluted)	-0.36	-0.65	-0.62	-0.69	-0.99
Free Cash Flow	-153	-183.21	-249.07	-400.67	-288.7
Free Cash Flow Per Share	-0.30	-0.36	-0.48	-0.78	-0.65
EBITDA	-141.6	-178.83	-231.11	-324.33	-333.99
D&A For EBITDA	59.3	52.22	43.11	20.82	13.74
EBIT	-200.9	-231.05	-274.22	-345.15	-347.72

Source: S&P Global Market Intelligence. Standard template. Financial Sources.